Lung cell transplantation for the treatment of lung fibrosis
AssigneeBoard of Regents, The University of Texas System
InventorsYair Reisner, Irit Milman Krentsis, Yangxi Zheng
Life of this patent
Estimating the term…
Abstract
Provided herein are lung forming progenitor cell therapies which do not require pre-conditioning treatments. Administration of the progenitor cells can replace or replenish populations of host-derived patch forming cells to reverse or inhibit fibrosis, promote healing, and improve lung function. Further disclosed herein are methods for monitoring fibrosis, and for determining whether a subject will be receptive to progenitor cell treatments.
Claims38
A method of treating pulmonary fibrosis in a subject comprising:
- administering to a subject having at least about 15% lung fibrosis a therapeutically effective amount of lung forming progenitor cells, thereby treating pulmonary fibrosis in the subject.
3-4. (canceled)
7-9. (canceled)
11-12. (canceled)
14-17. (canceled)
21-22. (canceled)
24-27. (canceled)
29-30. (canceled)
(canceled)
(canceled)
A method of improving lung function in a subject in need thereof comprising:
- administering to a subject having at least about 15% lung fibrosis a therapeutically effective amount of lung forming progenitor cells, thereby improving lung function in the subject.
(canceled)
39-42. (canceled)
A method of identifying a subject with pulmonary fibrosis as a candidate for treatment with lung forming progenitor cells comprising:
- a) measuring the level of fibrosis in the lungs of the subject;
- and
- i) classifying a subject with a level of fibrosis of at least about 15% or greater as a likely responder to cell transplantation, thereby identifying the subject as suitable for cell transplantation, or
- ii) classifying a subject with a level of fibrosis of about 0 to less than 15% as a likely non-responder to lung cell transplantation, thereby identifying the subject as unsuitable for cell transplantation,
- thereby identifying a subject with pulmonary fibrosis as a candidate for treatment with lung forming progenitor cells.
(canceled)
(canceled)
48-51. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.